From HPV infection to oncogenesis: A brief review of the complex immunobiological events

Current Cancer Therapy Reviews

Volumn 6, Issue 2, 2010, Pages 110-116

  Stern, Peter L ^a   Einstein, Mark H ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Antigen presenting cells (APC); Cytotoxic T lymphocytes (CTL); Human leucocyte antigen (HLA); Immune escape; Interferon; Neutralising antibodies; T regulatory cells

Indexed keywords

HEPARAN SULFATE; INTERLEUKIN 10; NEUTRALIZING ANTIBODY; PROTEIN E2; PROTEIN E6; PROTEIN E7; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS DNA; VIRUS PROTEIN; WART VIRUS VACCINE;

ADAPTIVE IMMUNITY; ANOGENITAL CANCER; ANTIGEN PRESENTING CELL; ARTICLE; BASAL CELL; BASEMENT MEMBRANE; CANCER IMMUNIZATION; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CLONAL ANERGY; CYTOKINE PRODUCTION; CYTOLOGY; EPITHELIUM CELL; GENE MUTATION; GENITAL TRACT CANCER; HUMAN; HUMORAL IMMUNITY; IMMUNOBIOLOGY; IMMUNOLOGY; IMMUNOSURVEILLANCE; INNATE IMMUNITY; LANGERHANS CELL; LIFE CYCLE; MEMORY CELL; MOLECULAR BIOLOGY; PAPILLOMATOSIS; PAPILLOMAVIRUS INFECTION; PERSISTENT INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY PAPILLOMATOSIS; RISK FACTOR; T LYMPHOCYTE; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIREMIA; VIRION; VIROLOGY; VIRUS GENOME; VIRUS IMMUNITY; VIRUS LIKE AGENT; VIRUS PARTICLE; VIRUS REPLICATION; WART VIRUS;

EID: 77952950068     PISSN: 15733947     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339410791202565     Document Type: Article

References (75)

1. Bosch FX, Burchell AN, Schiffman M, et al. Epidemiology and natural history of human papillomavirus infections and typespecific implications in cervical neoplasia. Vaccine 2008; 26 (Suppl 10): K1-16.
2. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-9.
3. Strickler HD, Burk RD, Fazzari M, et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst 2005; 97: 577-86.
4. Einstein MH, Leanza S, Chiu LG, et al. Genetic variants in TAP are associated with high-grade cervical neoplasia. Clin Cancer Res 2009; 15: 1019-23.
5. Wang SS, Bratti MC, Rodriguez AC, et al. Common variants in immune and DNA repair genes and risk for human papillomavirus persistence and progression to cervical cancer. J Infect Dis 2009; 199: 20-30.
6. Yu KJ, Bashirova A, Madeleine MM, et al. Evaluation of the association with cervical cancer of polymorphisms in syndecan-1, a heparan sulfate proteoglycan involved with viral cell entry. Cancer Epidemiol Biomarkers Prev 2007; 16: 2504-8.
7. Howley PM, Lowy DR. Papillomaviruses. In: DM K, PM H, Eds. Fields Virology. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins 2007; pp. 2299-354.
8. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 2006; 110: 525-41.
9. Shafti-Keramat S, Handisurya A, Kriehuber E, Meneguzzi G, Slupetzky K, Kirnbauer R. Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. J Virol 2003; 77: 13125-35.
10. Richards RM, Lowy DR, Schiller JT, Day PM. Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc Natl Acad Sci USA 2006; 103: 1522-7.
11. Roberts JN, Buck CB, Thompson CD, et al. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med 2007; 13: 857-61.
12. Roberts S, Young LS. Role of HPV in cervical carcinogenesis. In: Stern PL, Kitchener HC, Eds. Vaccines for the prevention of cervical cancer. Oxford, England: Oxford University Press 2009.
13. Conway MJ, Meyers C. Replication and assembly of human papillomaviruses. J Dent Res 2009; 88: 307-17.
14. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA 2007; 297: 813-9.
15. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 12; 338: 423-8.
16. Einstein MH, Cruz Y, El-Awady MK, et al. Utilization of the human genome sequence localizes human papillomavirus type 16 DNA integrated into the TNFAIP2 gene in a fatal cervical cancer from a 39-year-old woman. Clin Cancer Res 2002; 8: 549-54.
17. Duensing S, Munger K. Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins. Int J Cancer 2004; 109: 157-62.
18. Huang LW, Chao SL, Lee BH. Integration of human papillomavirus type-16 and type-18 is a very early event in cervical carcinogenesis. J Clin Pathol 2008; 61: 627-31.
19. Stanley MA. HPV-a master at avoiding the host's defences. HPV Today 2007; 11:1-16.
20. Frazer IH. Interaction of human papillomaviruses with the host immune system: a well evolved relationship. Virology 2009; 384: 410-4.
21. Einstein MH, Schiller JT, Viscidi RP, et al. Clinician's guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis 2009; 9: 347-56.
22. Stern PL. Immune control of HPV infection in cervical neoplasia In: Stern PL, Kitchener HC, Eds. Vaccines for the prevention of cervical cancer. Oxford, England: Oxford University Press 2009.
23. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18: 767-811.
24. Steinman RM, Hemmi H. Dendritic cells: translating innate to adaptive immunity. Curr Top Microbiol Immunol 2006; 311: 17-58.
25. Niedergang F, Didierlaurent A, Kraehenbuhl JP, Sirard JC. Dendritic cells: the host Achille's heel for mucosal pathogens? Trends Microbiol 2004; 12: 79-88.
26. Wang HY, Lee DA, Peng G, et al. Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity 2004; 20: 107-18.
27. Kalinski P, Hilkens CM, Wirerenga EA, Kapsenberg ML. T-cell priming by type 1 and type 2 polarized dendritic cells: concept of a third signal. Immunol Today 1999; 20: 561-7.
28. Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2002; 2: 251-62.
29. de Gruijl TD, Bontkes HJ, Stukart MJ, et al. T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection. J Gen Virol 1996; 77: 2183-91.
30. de Gruijl TD, Bontkes HJ, Walboomers JM, et al. Differential T helper cell responses to human papillomavirus type 16 E7 related to viral clearance or persistence in patients with cervical neoplasia: a longitudinal study. Cancer Res 1998; 58: 1700-6.
31. Bontkes HJ, de Gruijl TD, van den Muysenberg AJ, et al. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia. Int J Cancer 2000; 88: 92-8.
32. van der Burg SH, Ressing ME, Kwappenberg KM, et al. Natural Thelper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class IIrestricted epitopes. Int J Cancer 2001; 91: 612-8.
33. de Jong A, van Poelgeest MI, van der Hulst JM, et al. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res 2004; 64: 5449-55.
34. Farhat S, Nakagawa M, Moscicki AB. Cell-mediated immune responses to human papillomavirus 16 E6 and E7 antigens as measured by interferon gamma enzyme-linked immunospot in women with cleared or persistent human papillomavirus infection. Int J Gynecol Cancer 2009; 19: 508-12.
35. Schwarz TF. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention. Expert Rev Vaccines 2008; 7: 1465-73.
36. Viscidi RP, Schiffman M, Hildesheim A, et al. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev 2004;13: 324-7.
37. Hildesheim A, Herrero R, Wacholder S, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007; 298: 743-53.
38. Fausch SC, Da Silva DM, Rudolf MP, Kast WM. Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses. J Immunol 2002; 169: 3242-9.
39. Giannini SL, Hubert P, Doyen J, Boniver J, Delvenne P. Influence of the mucosal epithelium microenvironment on Langerhans cells: implications for the development of squamous intraepithelial lesions of the cervix. Int J Cancer 2002; 97: 654-9.
40. Tay SK, Jenkins D, Maddox P, Campion M, Singer A. Subpopulations of Langerhans' cells in cervical neoplasia. Br J Obstet Gynaecol 1987; 94:10-5.
41. Guess JC, McCance DJ. Decreased migration of Langerhans precursor-like cells in response to human keratinocytes expressing human papillomavirus type 16 E6/E7 is related to reduced macrophage inflammatory protein-3alpha production. J Virol 2005; 79: 14852-62.
42. Connor JP, Ferrer K, Kane JP, Goldberg JM. Evaluation of Langerhans' cells in the cervical epithelium of women with cervical intraepithelial neoplasia. Gynecol Oncol 1999; 75: 130-5.
43. Hubert P, Caberg JH, Gilles C, et al. E-cadherin-dependent adhesion of dendritic and Langerhans cells to keratinocytes is defective in cervical human papillomavirus-associated (pre)neoplastic lesions. J Pathol 2005; 206: 346-55.
44. Nees M, Geoghegan JM, Munson P, et al. Human papillomavirus type 16 E6 and E7 proteins inhibit differentiation-dependent expression of transforming growth factor-beta2 in cervical keratinocytes. Cancer Res 2000; 60: 4289-98.
45. Chang YE, Laimins LA. Microarray analysis identifies interferoninducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31. J Virol 2000; 74: 4174-82.
46. Barnard P, McMillan NA. The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-alpha. Virology 1999; 259: 305-13.
47. Li S, Labrecque S, Gauzzi MC, et al. The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha. Oncogene 1999;18: 5727-37.
48. Cho YS, Kang JW, Cho M, et al. Down modulation of IL-18 expression by human papillomavirus type 16 E6 oncogene via binding to IL-18. FEBS Lett 2001; 501:139-45.
49. Hasan UA, Bates E, Takeshita F, et al. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol 2007;178:3186-97.
50. Zhang B, Li P, Wang E, et al. The E5 protein of human papillomavirus type 16 perturbs MHC class II antigen maturation in human foreskin keratinocytes treated with interferon-gamma. Virology 2003; 310:100-8.
51. Belkaid Y, Tarbell K. Regulatory T cells in the control of hostmicroorganism interactions (*). Annu Rev Immunol 2009; 27: 551-89.
52. van der Burg SH, Piersma SJ, de Jong A, et al. Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. Proc Natl Acad Sci USA 2007;104(29): 12087-92.
53. Fattorossi A, Battaglia A, Ferrandina G, et al. Lymphocyte composition of tumor draining lymph nodes from cervical and endometrial cancer patients. Gynecol Oncol 2004; 92: 106-15.
54. Molling JW, de Gruijl TD, Glim J, et al. CD4(+)CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia. Int J Cancer 2007; 121: 1749-55.
55. Bonagura VR, Hatam L, DeVoti J, Zeng F, Steinberg BM. Recurrent respiratory papillomatosis: altered CD8(+) T-cell subsets and T(H)1/T(H)2 cytokine imbalance. Clin Immunol 1999; 93: 302-11.
56. Bonagura VR, Vambutas A, DeVoti JA, et al. HLA alleles, IFNgamma responses to HPV-11 E6, and disease severity in patients with recurrent respiratory papillomatosis. Hum Immunol 2004; 65: 773-82.
57. DeVoti JA, Rosenthal DW, Wu R, Abramson AL, Steinberg BM, Bonagura VR. Immune dysregulation and tumor-associated gene changes in recurrent respiratory papillomatosis: a paired microarray analysis. Mol Med 2008; 14: 608-17.
58. DeVoti JA, Steinberg BM, Rosenthal DW, et al. Failure of gamma interferon but not interleukin-10 expression in response to human papillomavirus type 11 E6 protein in respiratory papillomatosis. Clin Diagn Lab Immunol 2004; 11: 538-47.
59. Rosenthal DW, DeVoti JA, Schmidmayerova H, Steinberg BM, Bonagura VR. Human Papillomavirus causes a TH2-like Chemokine Predominance in Recurrent Respiratory Papillomatotosis (RRP). J Allergy Clin Immunol 2008; 121:S15.
60. Rosenthal DW, DeVoti JA, Wu R, Schmidmayerova H, Steinberg BM, Bonagura VR. Recurrent respiratory papillomatosis (RRP): Increased TH2-like chemokine expression. J Allergy Clin Immunol 2006; 117: S104.
61. Rosenthal DW, Schmidmayerova H, Steinberg BM, et al. Recurrent respiratory papillomatosis (RRP): Disease severity associates with enhanced TH2-like dendritic cell chemokine (DC-CK1) plasma expression. J Allergy Clin Immunol 2005; 115: 81.
62. Hatam LJ, Rosenthal DW, DeVoti JA, et al. CD4+Foxp3+CD 127+low T-Regulatory cells are increased in HPV infected papillomas in patients with recurrent respiratory papillomatosis (RRP). J Allergy Clin Immunol 2008; 121: 211.
63. Clerici M, Merola M, Ferrario E, et al. Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection. J Natl Cancer Inst 1997; 89: 245-50.
64. al-Saleh W, Giannini SL, Jacobs N, et al. Correlation of T-helper secretory differentiation and types of antigen-presenting cells in squamous intraepithelial lesions of the uterine cervix. J Pathol 1998; 184: 283-90.
65. Herdman MT, Pett MR, Roberts I, et al. Interferon-beta treatment of cervical keratinocytes naturally infected with human papillomavirus 16 episomes promotes rapid reduction in episome numbers and emergence of latent integrants. Carcinogenesis 2006; 27: 2341-53.
66. Bontkes HJ, Walboomers JM, Meijer CJ, Helmerhorst TJ, Stern PL. Specific HLA class I down-regulation is an early event in cervical dysplasia associated with clinical progression. Lancet 1998; 351: 187-8.
67. Brady CS, Bartholomew JS, Burt DJ, et al. Multiple mechanisms underlie HLA dysregulation in cervical cancer. Tissue Antigens 2000; 55: 401-11.
68. Keating PJ, Cromme FV, Duggan-Keen M, et al. Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression. Br J Cancer 1995; 72: 405-11.
69. Koopman LA, Corver WE, van der Slik AR, Giphart MJ, Fleuren GJ. Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J Exp Med 2000; 191: 961-76.
70. Piersma SJ, Jordanova ES, van Poelgeest MI, et al. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res 2007; 67: 354-61.
71. Kadish AS, Einstein MH. Vaccine strategies for human papillomavirus-associated cancers. Curr Opin Oncol 2005; 17: 456-61.
72. Apple RJ, Becker TM, Wheeler CM, Erlich HA. Comparison of human leukocyte antigen DR-DQ disease associations found with cervical dysplasia and invasive cervical carcinoma. J Natl Cancer Inst 1995; 87: 427-36.
73. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 1928-43.
74. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 2006; 367: 489-98.
75. Sadler L, Saftlas A, Wang W, Exeter M, Whittaker J, McCowan L. Treatment for cervical intraepithelial neoplasia and risk of preterm delivery. JAMA. 2004; 291: 2100-6.